货号：R2263
储存条件：粉末-20°C可保存3年；液体-80°C可保存12月。
产品描述
The activated serine protease Factor Xa (FXa), activated by both the intrinsic and the extrinsic pathways, plays a central role in the blood coagulation cascade. FXa catalyzes the conversion of prothrombin tothrombin through the prothrombinase complex. Rivaroxaban, also called BAY 59-7939, is an inhibitor of FXa with IC50 of 0.7 nM and Ki of 0.4 nM which is under clinical development for the treatment of thrombotic disease. Rivaroxaban (15, 30, or 60 ng/mL) inhibited thrombin generation in a concentration-dependent manner and the effect was enhanced with ticagrelor (1.0 µg/mL) and ticagrelor plus acetylsalicylic acid (100 µg/mL). Rivaroxaban (0.01, 0.03, or 0.1 mg/kg) also dose-dependently reduced thrombus formation in arteriovenous shunt model in rats. Oral rivaroxaban (2.5 mg twice-daily [bid] and 5 mg bid) reduced mortality and morbidity in patients with acute coronary syndrome, when combined with antiplatelets.
作用机制
Rivaroxaban forms two hydrogen bonds to Gly219 of Factor Xa.
储存液制备 | 质量 | 1 mg | 5 mg | 10 mg |
1 mM | 2.2942 mL | 11.4710 mL | 22.9421 mL | |
5 mM | 0.4588 mL | 2.2942 mL | 4.5884 mL | |
10 mM | 0.2294 mL | 1.1471 mL | 2.2942 mL |
产品信息
CAS号 | 366789-02-8 | |
分子式 | C19H18ClN3O5S | |
分子量 | 435.88 | |
溶解度
| DMSO | 86.0 mg/mL (197.3 mM) |
Water | Insoluble | |
Ethanol | Insoluble | |
说明书下载
